In this IPD meta-analysis, no statistically significant differences in PFS and OS were observed between PD-1 inhibitors or PD-L1 inhibitors plus chemotherapy as first-line treatment of ES-SCLC. Here, PDCD1 is linked to small cell lung carcinoma.